eligibility_summary
Adults (≥18) with r/r B‑cell lymphoma (LBCL, FL, MZL, MCL) after ≥2 prior lines incl anti‑CD20, Burkitt after ≥1. Expansion: r/r LBCL or FL3B. Prior FMC63 CD19 CAR allowed. Need ECOG 0–1, measurable disease, and adequate counts/organ function. Key exclusions: CNS involvement, non‑FMC63 CAR, recent SCT/GVHD, autoimmune requiring immunosuppression, major cardiac disease, active infection/HIV/HBV/HCV viremia, live vaccine ≤6 wks, pregnancy/breastfeeding, contraception required.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: JV-213, an autologous CD79b-targeted chimeric antigen receptor (CAR) T-cell therapy (cellular gene therapy) administered IV after leukapheresis. Mechanism: Patient T cells are genetically engineered to express a CAR that binds CD79b (Igβ), a component of the B-cell receptor (BCR) complex, CAR engagement activates T cells, inducing proliferation, cytokine release, and perforin/granzyme-mediated cytotoxicity against CD79b+ cells. Targets: Malignant B cells in r/r B-cell lymphomas (LBCL incl DLBCL/HGBCL/PMBCL/transformed, FL grade 3B, MZL, MCL, Burkitt). Pathway/cellular target: CD79b within the BCR signaling complex on B cells. Phase 1, dose escalation/expansion.